HOME > NATIONAL > Article

Text Size

small

medium

large


Japan to Cut Price of Alzheimer's Drug Lecanemab

Japan to Cut Price of Alzheimer's Drug Lecanemab

Lecanemab, an Alzheimer's disease drug codeveloped by Japan's Eisai Co. and Biogen Inc. of the United States (Courtesy of Eisai)
Lecanemab, an Alzheimer's disease drug codeveloped by Japan's Eisai Co. and Biogen Inc. of the United States (Courtesy of Eisai)

   Tokyo, July 10 (Jiji Press)--Japan is expected to lower the price of lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and Biogen Inc. of the United States, following a health ministry panel's report citing its low cost-effectiveness.
   Based on the assessment report, the ministry is expected to cut the official price of the drug by up to 15 pct from the current level of about 3 million yen per patient a year.
   The report, submitted to the Central Social Insurance Medical Council, which advises the health minister, on Wednesday, pointed to lecanemab's lower cost-effectiveness compared with conventional Alzheimer's drugs such as donepezil.
   The margin of the expected price cut will be formally decided after the council discusses lecanemab's effect in reducing costs of public nursing care services.
   Lecanemab is innovative because it removes abnormal proteins that accumulate in patients' brains, hopefully slowing the progression of the disease.

To read a full story, please click here to find out how to subscribe.

NATIONAL

HEADLINES

POLITICS
Japan, US, Philippine Foreign Chiefs Discuss South, East China Sea Situations
ECONOMY
Tokyo Metro, JR East, Others Start Parasol Rental Service at Stations in Tokyo
SPORTS
Japan Pro Baseball: Hanshin Tigers Extend Winning Streak to 11th Game
OTHER
Quake Evacuees from Japan's Tokara Islands May Return Home Starting Wed.

AFP-JIJI PRESS NEWS JOURNAL


Photos